OBJECTIVE: To collect data on the efficacy and safety of omalizumab in 110 patients from 9 Spanish hospitals suffering from chronic spontaneous urticaria (CSU) refractory to conventional treatment. METHODS: A retrospective, descriptive analysis was performed, showing the data of 110 patients suffering from refractory CSU who received omalizumab as an off-label treatment in 9 Spanish hospitals from October 2009 to September 2012. RESULTS: Ninety (81.8%) patients exhibited a complete or significant response, 12 (10.9%) had partial response, and 8 (7.2%) showed no response. Sixty-six (60%) patients were able to stop all concomitant medications, remaining asymptomatic treated with omalizumab alone. No serious adverse events were reported. CONCLUSIONS: Omalizumab shows excellent efficacy and safety profile in a large series of CSU patients in real-life practice. This drug will contribute to settle the debt with CSU patients contributing to restore their quality of life.
OBJECTIVE: To collect data on the efficacy and safety of omalizumab in 110 patients from 9 Spanish hospitals suffering from chronic spontaneous urticaria (CSU) refractory to conventional treatment. METHODS: A retrospective, descriptive analysis was performed, showing the data of 110 patients suffering from refractory CSU who received omalizumab as an off-label treatment in 9 Spanish hospitals from October 2009 to September 2012. RESULTS: Ninety (81.8%) patients exhibited a complete or significant response, 12 (10.9%) had partial response, and 8 (7.2%) showed no response. Sixty-six (60%) patients were able to stop all concomitant medications, remaining asymptomatic treated with omalizumab alone. No serious adverse events were reported. CONCLUSIONS:Omalizumab shows excellent efficacy and safety profile in a large series of CSU patients in real-life practice. This drug will contribute to settle the debt with CSU patients contributing to restore their quality of life.
Authors: Michael D Tharp; Jonathan A Bernstein; Abhishek Kavati; Benjamin Ortiz; Karen MacDonald; Kris Denhaerynck; Ivo Abraham; Christopher S Lee Journal: JAMA Dermatol Date: 2019-01-01 Impact factor: 10.282
Authors: Sinisa Savic; Alexander Marsland; David McKay; Michael R Ardern-Jones; Tabi Leslie; Olivier Somenzi; Laura Baldock; Clive Grattan Journal: Allergy Asthma Clin Immunol Date: 2015-07-21 Impact factor: 3.406
Authors: M Ferrer; J Bartra; A Giménez-Arnau; I Jauregui; M Labrador-Horrillo; J Ortiz de Frutos; J F Silvestre; J Sastre; M Velasco; A Valero Journal: Clin Exp Allergy Date: 2015-04 Impact factor: 5.018
Authors: Paul Wilches; Paola Wilches; Juan Carlos Calderon; Annia Cherrez; Ivan Cherrez Ojeda Journal: World Allergy Organ J Date: 2016-11-23 Impact factor: 4.084
Authors: Victor D Mandel; Mario B Guanti; Serena Liberati; Antongiulio Demonte; Giovanni Pellacani; Patrizia Pepe Journal: Dermatol Ther (Heidelb) Date: 2018-05-16